NCT02679339View on ClinicalTrials.gov

Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Acute-onset Herpes Zoster Pain
Interventions
DRUG

CNTX-2022 (lidocaine gel, 40%)

DRUG

Placebo

Trial Locations (1)

Unknown

Nucleus Network, Melbourne

Sponsors
All Listed Sponsors
lead

Centrexion Therapeutics

INDUSTRY

NCT02679339 - Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain | Biotech Hunter | Biotech Hunter